Cargando…

A novel patient-derived 3D model recapitulates mantle cell lymphoma lymph node signaling, immune profile and in vivo ibrutinib responses

Mantle cell lymphoma (MCL), a rare and aggressive B-cell non-Hodgkin lymphoma, mainly develops in the lymph node (LN) and creates a protective and immunosuppressive niche that facilitates tumor survival, proliferation and chemoresistance. To capture disease heterogeneity and tumor microenvironment (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Araujo-Ayala, Ferran, Dobaño-López, Cèlia, Valero, Juan García, Nadeu, Ferran, Gava, Fabien, Faria, Carla, Norlund, Marine, Morin, Renaud, Bernes-Lasserre, Pascale, Serrat, Neus, Playa-Albinyana, Heribert, Giménez, Rubén, Campo, Elías, Lagarde, Jean-Michel, López-Guillermo, Armando, Gine, Eva, Colomer, Dolors, Bezombes, Christine, Pérez-Galán, Patricia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10244172/ https://www.ncbi.nlm.nih.gov/pubmed/37031299 http://dx.doi.org/10.1038/s41375-023-01885-1

Ejemplares similares

Challenges with Approved Targeted Therapies against Recurrent Mutations in CLL: A Place for New Actionable Targets
por: López-Oreja, Irene, et al.
Publicado: (2021)

Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies
por: Delgado, Julio, et al.
Publicado: (2020)

Follicular Lymphoma Microenvironment: An Intricate Network Ready for Therapeutic Intervention
por: Dobaño-López, Cèlia, et al.
Publicado: (2021)

Systems biology drug screening identifies statins as enhancers of current therapies in chronic lymphocytic leukemia
por: Gimenez, Neus, et al.
Publicado: (2020)

Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial
por: Giné, Eva, et al.
Publicado: (2022)

SF3B1 mutation–mediated sensitization to H3B-8800 splicing inhibitor in chronic lymphocytic leukemia
por: López-Oreja, Irene, et al.
Publicado: (2023)

Tumorigenic role of Musashi-2 in aggressive mantle cell lymphoma
por: Sureda-Gómez, Marta, et al.
Publicado: (2022)

The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia
por: Xargay-Torrent, Sílvia, et al.
Publicado: (2015)

Cryptococcal meningoencephalitis in patients with mantle cell lymphoma on ibrutinib
por: Sun, Kai, et al.
Publicado: (2018)

3D Model Characterization by 2D and 3D Imaging in t(14;18)-Positive B-NHL: Perspectives for In Vitro Drug Screens in Follicular Lymphoma
por: Gava, Fabien, et al.
Publicado: (2021)

All-CLL: A Capture-based Next-generation Sequencing Panel for the Molecular Characterization of Chronic Lymphocytic Leukemia
por: López-Oreja, Irene, et al.
Publicado: (2023)

Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens
por: Vidal-Crespo, Anna, et al.
Publicado: (2020)

Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia
por: Giménez, Neus, et al.
Publicado: (2019)

Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
por: Peterson, Derek, et al.
Publicado: (2014)

Ibrutinib Is Effective in the Treatment of Autoimmune Haemolytic Anaemia in Mantle Cell Lymphoma
por: Galinier, Aliénor, et al.
Publicado: (2017)

Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma
por: Zhao, Xiaohong, et al.
Publicado: (2017)

Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma
por: Zhao, Xiaohong, et al.
Publicado: (2021)

Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma
por: Li, Lingzhi, et al.
Publicado: (2022)

Ibrutinib: Implications for Use in the Treatment of Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
por: McNally, Gretchen Anne, et al.
Publicado: (2015)

Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma
por: Maruyama, Dai, et al.
Publicado: (2016)

Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma
por: Portell, Craig A., et al.
Publicado: (2022)

CD52 and OXPHOS—potential targets in ibrutinib-treated mantle cell lymphoma
por: Fuhr, Viktoria, et al.
Publicado: (2022)

Patient-derived lymphoma spheroids integrating immune tumor microenvironment as preclinical follicular lymphoma models for personalized medicine
por: Faria, Carla, et al.
Publicado: (2023)

Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXA
por: Heine, Simon, et al.
Publicado: (2018)

Identification by mass spectrometry and immunoblotting of xenogeneic antigens in the N- and O-glycomes of porcine, bovine and equine heart tissues
por: Jin, Chunsheng, et al.
Publicado: (2020)

A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia
por: Tucker, David L, et al.
Publicado: (2015)

Ibrutinib Caused Mediastinal Emphysema and Pneumothorax in the Treatment of a Patient with Mantle Cell Lymphoma
por: Tsutsumi, Yutaka, et al.
Publicado: (2019)

Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real‐world experience
por: Jeon, Young‐Woo, et al.
Publicado: (2019)

PB2072: EFFICACY AND SIDE EFFECTS OF IBRUTINIB IN RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA
por: Basturk, A., et al.
Publicado: (2022)

Patterns of change in treatment, response, and outcome in patients with follicular lymphoma over the last four decades: a single-center experience
por: Mozas, Pablo, et al.
Publicado: (2020)

Cell-Free DNA for Genomic Analysis in Primary Mediastinal Large B-Cell Lymphoma
por: Rivas-Delgado, Alfredo, et al.
Publicado: (2022)

CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia
por: Montraveta, Arnau, et al.
Publicado: (2015)

NR4A1 inhibition synergizes with ibrutinib in killing mantle cell lymphoma cells
por: Li, Yangguang, et al.
Publicado: (2017)

CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma
por: Mohanty, Atish, et al.
Publicado: (2016)

Diffuse Alveolar Hemorrhage Secondary to Ibrutinib Therapy in a Patient With Refractory Mantle Cell Lymphoma
por: Locke, Clifford B, et al.
Publicado: (2020)

A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma
por: Qualls, David, et al.
Publicado: (2022)

Unraveling the genetics of transformed splenic marginal zone lymphoma
por: Grau, Marta, et al.
Publicado: (2023)

Serum monoclonal component in chronic lymphocytic leukemia: baseline correlations and prognostic impact
por: Mozas, Pablo, et al.
Publicado: (2020)

Bcl-2(high) mantle cell lymphoma cells are sensitized to acadesine with ABT-199
por: Montraveta, Arnau, et al.
Publicado: (2015)

Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment
por: Rudelius, Martina, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6ediqubtl6v6aemniqsc58klc0